|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Geek Squad V. Gizmodo
- Social Networking's 'Naked' Truth
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Dykstra Discusses Bankruptcy
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
Text Size 
GlaxoSmithKline, [GSK
Loading...
()
] Europe's biggest drug maker, reported a 16% rise in annual profit Thursday, in line with expectations of analysts polled by Reuters. But the company said 2007 growth would slow as it awaits pipeline renewal.
Fourth-quarter profit before tax was $2.2 billion, up from $2.08 billion in the same three months ending December in 2005.
Sales in the fourth-quarter rose to $7.79 billion from $7.66 billion, helped by strong U.S. demand.
For the coming year, GSK forecast EPS growth in constant exchange rate terms of between 8% to 10% -- better than the low single-digit level some analysts had expected.
GSK said that it plans launch 5 major new pharmaceutical products in 2007:Tykerb, which is a breast cancer drug; Allermist/Avamys, a allergic rhinitis treatment; Coreg, for treating heart conditions and Trexima for migraines. The company also, said that it expects to file for U.S. approval for cervical cancer vaccine Cervarix in April.
Competition from generic drug makers will increase for major pharmaceuticals in 2007, and GSK is no exception with both its anti-nausea drug Zofran and anti-depressant Wellbutrin XL set to face new rivals.
The company's shares rose more than 1% in London in reaction to the results.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes